Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiho Pharmaceutical Co. Ltd.

Division of Otsuka Holdings Co. Ltd.
www.taiho.co.jp

Latest From Taiho Pharmaceutical Co. Ltd.

Elevar Aims For Rivoceranib Turnaround After Positive Phase III Update

Despite failing to meet the primary endpoint in recent top-line Phase III results, Elevar Therapeutics (formerly LSK BioPharma) is hopeful that rivoceranib still has potential in late-stage gastric cancer based on generally positive full efficacy data from the global Phase III study presented at ESMO.

Clinical Trials Cancer

Deal Watch: BMS To Tap Early-Stage Breakthroughs In Partnership With BioMotiv

Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.

Deals Business Strategies

Evotec DNA Damage Response Spin-Out Aims For First IND-Ready Drug In 2022

Evotec’s chief science officer tells Scrip the German biotech is putting its cancer therapeutic program focused on DNA damage response into a new spin-off that aims to have an IND-ready drug in 2022.

Companies Cancer

Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate

While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.

Business Strategies Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Otsuka Holdings Co. Ltd.
  • Senior Management
  • Masayuki Kobayashi, Pres.
  • Contact Info
  • Taiho Pharmaceutical Co. Ltd.
    Phone: (81) 3 3294 4527
    1-27 Kandanishiki-Cho
    Chiyoda-Ku
    Tokyo, 101-8444
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register